NCT06148948View on ClinicalTrials.gov

A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

December 25, 2023

Primary Completion Date

May 21, 2024

Study Completion Date

May 21, 2024

Conditions
Healthy
Interventions
DRUG

BI 1584862

BI 1584862

DRUG

Placebo

Placebo matching BI 1584862

Trial Locations (1)

130-0004

SOUSEIKAI Sumida Hospital, Tokyo, Sumida-ku

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06148948 - A Study in Healthy Men to Test How Well Different Doses of BI 1584862 Are Tolerated | Biotech Hunter | Biotech Hunter